The Flow Cytometry Shared Resource (FCSR) provides state-of-the-art analytical and sorting instrumentation as well as cutting-edge expertise, at an affordable cost, to UCLA investigators needing flow cytometry to pursue their research. The Jonsson Comprehensive Cancer Center (JCCC) established this campus-wide shared resource in 1988. Dr. Jamieson (Tl), an accomplished cellular immunologist, has been the Director of the FCSR since 2000. Ms. Schmid, the manager of the FCSR since 1988, is responsible for the daily operation of the FCSR and assists Dr. Jamieson (Tl) with long-term planning. Both Dr. Jamieson (Tl) and Ms. Schmid are available to users for consultation. To achieve its goals, the FCSR provides five analytic flow cytometers, three high-speed digital cell sorters, an AutoMACS cell separator and a free-standing analysis station. The FCSR is easily accessible and is responsible for procurement, daily calibration, maintenance and repair of all instrumentation. FCSR personnel have a combined 82 years of experience in flow cytometry;their expertise is available to investigators through one-on-one consultation, classes, a website, poster presentations and open houses. Ms. Schmid and Dr. Jamieson (Tl) also work with researchers to adapt, or develop, assays to enable investigators to pursue research questions in novel ways. FCSR services help researchers with a wide range of experience in flow cytometry to perform high quality assays, with minimal time expenditure. Workshops, seminars and utilization of new assays ensure that researchers remain on the cutting-edge of flow cytometry without the necessity of investing their own funds or staff time to keep current in the latest advances. Cytometric instrumentation is expensive and beyond the budget of most individual researchers;therefore, the FCSR provides instrumentation, as well as additional cost savings to researchers, by obtaining grant and institutional support to help offset the cost of purchasing, maintaining and operating those instruments. The cost savings are passed on to the researcher. During the last funding period, a total of 254 investigators used the FCSR. Between July 1, 2006, through June 30, 2007 (the reporting period for the CCSG competing renewal), JCCC members were responsible for 76% of the usage. These data objectively demonstrate the role of the FCSR in enhancing cancer research at UCLA and its contribution to JCCC's effort to improving diagnosis, therapy and cure of cancer patients. (Please also see Section 6.2.3 on Shared Resources in the History, Description, Essential Characteristics). 86 Cancer Center members representing 11 Cancer Center Program Areas utilized the services of the Flow Cytometry Shared Resource during the reporting period. This is a continuing shared resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016042-38
Application #
8392134
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
38
Fiscal Year
2013
Total Cost
$211,423
Indirect Cost
$66,160
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7

Showing the most recent 10 out of 192 publications